B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells
Yu W, Chen L, Guo S, Luo L, Chen L. B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells. OncoImmunology 2018, 7: e1504156. PMID: 30574431, PMCID: PMC6298416, DOI: 10.1080/2162402x.2018.1504156.Peer-Reviewed Original ResearchAllogeneic T cellsT cellsB7-H1Systemic inflammationPD-1B7-H1 monoclonal antibodyB7-H1/PDAllogeneic T-cell responsesB7-H1 mAbProgression of GVHDT cell responsesCo-inhibitory pathwaysT-cell lysisLong-term toleranceHost cell destructionNormal hematopoietic cellsDisseminated inflammationHost diseaseLeukemia responseAccelerated progressionMouse modelCell destructionInflammationMonoclonal antibodiesTypes of cellsB7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction
Chen L, Azuma T, Yu W, Zheng X, Luo L, Chen L. B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proceedings Of The National Academy Of Sciences Of The United States Of America 2018, 115: 3126-3131. PMID: 29507197, PMCID: PMC5866601, DOI: 10.1073/pnas.1722043115.Peer-Reviewed Original ResearchConceptsB7-H1 expressionDendritic cellsT cell responsesB7-H1CTL responsesTumor escapeB7-H1/PDCell responsesSubdominant T-cell responsesPolyclonal T cell responsesCombination cancer immunotherapyDifferent dendritic cellsAdaptive resistanceT lymphocyte destructionAdvanced human cancersMurine tumor modelsSurvival benefitTumor AgDominant AgAntibody blockadeCancer immunotherapyDC functionImmune destructionLymphocyte destructionT lymphocytes